SAE Stock Chart & Stats
CHF62.30
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF62.30
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF27.80 - CHF66.50
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
CHF1.21B
Enterprise ValueCHF1.61K
Total Cash (Recent Filing)CHF118.90M
Total Debt (Recent Filing)CHF354.70M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Oct 29, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding20,578,390
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.85
Price to Sales (P/S)0.45
P/FCF Ratio-23.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF85.21Price Target Upside36.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.35
Revenue Forecast (FY)CHF3.20B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained revenue expansion shows the platform is gaining scale across European pharmacy and health categories. Continued growth can improve purchasing leverage, fulfillment efficiency and customer economics, supporting the long-term path toward profitability.
Improving Operating ProfitabilityThe rising EBITDA margin indicates operating leverage is beginning to emerge as revenue scales. If maintained, better contribution from centralized fulfillment and digital infrastructure could gradually offset customer acquisition and logistics costs.
Very Low Latest DebtThe latest debt reduction materially lowers interest and refinancing risk, giving Redcare greater flexibility to invest in growth and absorb operating volatility. This benefit remains meaningful if the unusually low debt level is sustained.
Bears Say
Persistent Net LossesRedcare has not yet converted substantial revenue growth into consistent bottom-line earnings. Persistent losses can limit internally funded expansion and may require continued cost discipline before the business demonstrates durable profitability.
Negative Free Cash FlowNegative free cash flow reduces financial flexibility despite the stronger balance sheet. Ongoing reinvestment and working-capital needs may require external funding or tighter spending, making cash conversion a key constraint on sustainable growth.
Negative Returns On EquityNegative returns on equity show that the capital base is not yet generating economic returns for shareholders. Unless margins improve enough to produce sustained earnings, continued losses could gradually weaken equity and constrain long-term value creation.
SAE FAQ
What was Redcare Pharmacy’s price range in the past 12 months?
Redcare Pharmacy lowest stock price was CHF27.80 and its highest was CHF66.50 in the past 12 months.
What is Redcare Pharmacy’s market cap?
Redcare Pharmacy’s market cap is CHF1.21B.
When is Redcare Pharmacy’s upcoming earnings report date?
Redcare Pharmacy’s upcoming earnings report date is Oct 29, 2026 which is in 70 days.
How were Redcare Pharmacy’s earnings last quarter?
Redcare Pharmacy released its earnings results on Jul 29, 2026. The company reported CHF0.214 earnings per share for the quarter, beating the consensus estimate of -CHF0.252 by CHF0.465.
Is Redcare Pharmacy overvalued?
According to Wall Street analysts Redcare Pharmacy’s price is currently Undervalued.
Does Redcare Pharmacy pay dividends?
Redcare Pharmacy does not currently pay dividends.
What is Redcare Pharmacy’s EPS estimate?
Redcare Pharmacy’s EPS estimate is 0.06.
How many shares outstanding does Redcare Pharmacy have?
Redcare Pharmacy has 20,578,390 shares outstanding.
What happened to Redcare Pharmacy’s price movement after its last earnings report?
Redcare Pharmacy reported an EPS of CHF0.214 in its last earnings report, beating expectations of -CHF0.252. Following the earnings report the stock price went up 1.284%.
Which hedge fund is a major shareholder of Redcare Pharmacy?
Currently, no hedge funds are holding shares in CH:SAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Redcare Pharmacy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF85.21 (36.78% Upside)
CHF85.21 (36.78% Upside)
Insider Transactions
Sold Shares
Worth CHF157.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.04%
Trailing 12-Months
Company Description
Redcare Pharmacy
Redcare Pharmacy N.V. manages and runs a network of digital pharmacies across Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. The company offers a comprehensive selection of healthcare products, including prescription medications, over-the-counter drugs, pharmacy-related beauty and personal care items, and nutritional supplements. Established in 2001, the firm, initially known as Shop Apotheke Europe N.V., officially rebranded to Redcare Pharmacy N.V. in June 2023. Its operational headquarters are situated in Sevenum, the Netherlands.
SAE Stock 12 Month Forecast
Average Price Target
CHF85.21
▲(36.78% Upside)